ArticleJACC. CardioOncology2023
Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk in Patients With Solid Cancer.
Article in JACC. CardioOncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Stroke secondary to cancer-associated coagulopathy: a systematic review.Journal of neurology · 2026Pooled it
- Development and validation of a risk assessment tool for ischemic stroke in cancer patients.Scientific reports · 2025Article
- Arterial Thromboembolism Incidence in Japanese Patients With Lung Cancer.Cancer medicine · 2025Article
- Inconsistent and Inaccurate Cancer Clinical Trial Reporting of Venous and Arterial Thrombotic Events: An Urgent Call to Action.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- The Growing Intersection Between Cancer and Cardiovascular Disease.JACC. CardioOncology · 2025Article
- Risk Factors for Arterial Thromboembolic Events in Male Germ Cell Tumors Treated with Chemotherapy.Cancers · 2025Article
- Cerebrovascular and Peripheral Vascular Complications in Cancer Patients.Current neurology and neuroscience reports · 2025Review
- Incidence and risk of arterial thromboembolism in cancer patients from a safety-net healthcare system.Journal of thrombosis and haemostasis : JTH · 2025Article
- Genetic Background in Patients with Cancer Therapy-Induced Cardiomyopathy.Journal of clinical medicine · 2025Review
- Solid Tumors, Liquid Challenges: The Impact of Coagulation Disorders.Hematology reports · 2025Review
- Cancer-associated thromboses in non-small cell lung cancer patients withContemporary oncology (Poznan, Poland) · 2025Article
- Time Relationship between the Occurrence of a Thromboembolic Event and the Diagnosis of Hematological Malignancies.Cancers · 2024Article
- Review
- Epidemiology and Antithrombotic Therapy for Cancer-Associated Arterial Thromboembolism in Japan.JACC. CardioOncology · 2024Article
- Arterial Thromboembolism in Japanese Patients With Cancer: Incidence, Predictors, and Survival Impact.JACC. CardioOncology · 2024Article
- Cancer and arterial thrombosis: therapeutic options.Research and practice in thrombosis and haemostasis · 2024Article
- Tumor Genetics Are Thrombogenic: The Need for Action.JACC. CardioOncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 3 countries.
Funding
Abstract
Background: Patients with cancer have an increased risk for arterial thromboembolism (ATE). Scant data exist about the impact of cancer-specific genomic alterations on the risk for ATE. Objectives: The aim of this study was to determine whether individual solid tumor somatic genomic alterations influence the incidence of ATE. Methods: A retrospective cohort study was conducted using tumor genetic alteration data from adults with solid cancers who underwent Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets testing between 2014 and 2016. The primary outcome, ATE, was defined as myocardial infarction, coronary revascularization, ischemic stroke, peripheral arterial occlusion, or limb revascularization and identified through systematic electronic medical record assessments. Patients were followed from date of tissue-matched blood control accession to first ATE event or death, for up to 1 year. Cause-specific Cox proportional hazards regression was used to determine HRs of ATE for individual genes adjusted for pertinent clinical covariates. Results: Among 11,871 eligible patients, 74% had metastatic disease, and there were 160 ATE events. A significantly increased risk for ATE independent of tumor type was noted for the Conclusions: In a large genomic tumor-profiling registry of patients with solid cancers, alterations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.